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The escalating emergence of AMR is a growing public health concern, and a result of the use 
and misuse of antibiotics since its introduction. To prevent the development of resistance 
and preserve the efficacy of antimicrobial agents, new treatment strategies is of utmost 
importance. One possible approach may be to take advantage of collateral sensitivity, a 
phenomenon where bacteria acquiring resistance to one antimicrobial drug simultaneously 
became more sensitive to others. Our aim in this project is to investigate the generality of 
collateral sensitivity in clinical urinary tract isolates of E. coli. In addition, we wanted to 
investigate effects of the mutations on biofilm forming ability of the resistant mutants. 
Methods 
In this study we generated mecillinam and/or ciprofloxacin resistant mutants in clinical 
isolates of E. coli. The generated mutants were further characterized by determining IC90 
values to investigate how the selection for resistance may have affected their susceptibility 
to six other antimicrobials. The results were eventually displayed in heatmaps. Biofilm 
forming ability of the wild-type strains and resistant isolates was investigated using a 
standard microtiter plate assay, detecting biofilm by crystal violet staining. 
Results 
Our results show that the resistant isolates of ciprofloxacin and mecillinam demonstrated 
different collateral sensitivity and cross-resistance effects in clinical isolates of E. coli. The 
isolates being resistant to both antibiotics tend to be largely dominated by the cross-
resistance effects seen for the isolates resistant to ciprofloxacin alone. Our results also show 
the resistant isolates generally are not producing much biofilms 
Conclusion 
Based on our in vitro results, we suggest that mecillinam is an applicable drug to use in the 
first-line treatment of UTIs. We also suggest that ciprofloxacin should be used prudently due 
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The discovery of penicillin by Alexander Fleming in 1928 has been recognized as one of the 
greatest scientific achievements in the late 19th century. The introduction of antimicrobials 
represented a revolution in the field of medicine, as countless lives have been saved from a 
variety of infections [2]. Despite knowledge about antimicrobial resistance (AMR) since the 
dawn of the antibiotic era an escalating emergence of resistant bacteria, coupled with a 
diminished interest in the discovery of novel drugs, has made "superbugs" a threat to public 
health worldwide [3].  
The rapid emergence of AMR is an inevitable outcome of antimicrobial use and misuse in 
health-care and agriculture, as well as the release of antimicrobials into the environment. 
Bacteria either possess innate characteristics making them resistant to certain antibiotics, or 
initially susceptible bacteria may develop different survival mechanisms to resist selective 
antimicrobial pressure [4]. The evolution and spread of multidrug-resistant bacteria are 
associated with increased mortality and morbidity, attributed to an estimated 25 000 deaths 
and at least €1,5 billion in extra health care costs annually in Europe alone [5]. Moreover, in 
addition to the limiting management of infectious disease, the burden of resistant bacteria 
will also have a detrimental effects on medical procedures such as chemotherapy, surgery, 
haemodialysis and organ transplantations, since antimicrobial therapy is a prerequisite for 
the success of these procedures [5]. 
Despite the urgent need for new drugs, several factors have led to a flagging interest in 
antibiotic development by the pharmaceutical industry [3]. While awaiting the development 
of novel treatment options, implementing antimicrobial stewardship programs focused on 
prudent the use of currently available antibiotics is of importance to prolong the life-span of 
remaining effective agents [6]. In 2013 Imamovic and Sommer proposed a novel drug cycling 
program focusing on collateral sensitivity as a promising treatment strategy to combat AMR 





also become more susceptible to others, was first described back in 1952 [7], it has been 
largely disregarded within microbiology until recently.  
In this project, the generality of collateral sensitivity (CS) and cross-resistance (CR) profiles 
will be investigated in clinical Escherichia coli isolates with laboratory-selected resistant to 
mecillinam and ciprofloxacin, as well isolates resistant to both antimicrobials. Additionally, 
we investigate if the mechanisms involved in the observed resistance in the mutants affect 
the ability of the isolates to form microbial biofilms. 
 
1.2 Antibacterial agents 
Antibacterial agents, more commonly referred to as antibiotics, are a group of chemical 
substances used to treat bacterial infections. The great success of these drugs is owed much 
to their ability to selectively target bacterial cells, either by inhibiting growth of the 
microorganisms (bacteriostatic) or by killing them (bactericidal), while having minimal 
effects on the host cells and tissues. Further, these agents can be categorized depending on 
the range of bacterial species that they are effective against; traditional broad-spectrum 
agents usually act against a wide range of bacteria of both Gram-negatives and Gram-
positives, whereas narrow-spectrum agents only target specific types bacteria.  
Most antimicrobials can be classified according to their principal mode of action. The four 
main groups interfere with one of the following essential processes in bacteria; cell wall 
synthesis, protein synthesis, nucleic acid synthesis or folate synthesis.  
 
1.2.1 Drug target - Cell wall  
The bacterial cell wall is composed of the polymer peptidoglycan. Peptidoglycan is present 
only in species belonging to the domain of Bacteria, making the cell wall an important 
antimicrobial target [8]. The peptidoglycan cell wall is found in both Gram-negative and 
Gram-positive bacteria, protecting the bacterial cell against osmotic pressure that can lead 





The late steps in cell wall formation involve the cytoplasmic synthesis of building blocks 
composed of N-acetyl muramic acid (NAM) linked to N-acetyl glucosamine (NAG) with an 
attached pentapeptide side chain [8, 9]. Penicillin binding proteins (PBPs), perform extensive 
cross-linking of the peptide side chains, thereby producing the mature, lattice-like 
peptidoglycan layer [8, 9]. β-lactams (e.g. mecillinam) are presumably the most well-known 
cell wall inhibitors. These antimicrobials interact directly with different types of PBPs, thus 
preventing the bacterial cell from maintaining its shape and osmotic stability [9]. 
Vancomycin, a glycopeptide antimicrobial, is another cell wall inhibitor that, although binds 
to a target different from the β-lactams, blocks the same step by producing steric hindrance 
to transpeptidase action [9]. 
 
1.2.2 Drug target - Protein synthesis 
The vast majority of proteins are either catalytic (enzymes) or structural proteins, both are 
vital components for the bacterial cell and essential for cellular function. Ribosomes 
synthesize proteins by building chains of amino acids in specific sequences [8].  
The prokaryotic ribosome consists of the 30S and 50S ribosomal subunits and is structurally 
different from the eukaryote ribosome [8]. Several classes of antimicrobials agents interfere 
with bacterial protein synthesis by targeting one or both of the subunits [10]. 
Aminoglycosides exhibit a bactericidal effect by binding to the 30S subunit, causing 
misreading of the genetic code [10]. Tetracycline also binds to the 30S subunit, but since its 
binding is transient, it exhibits bacteriostatic effect [10]. Macrolides bind to the 50S subunit 
and can have either a bacteriostatic and bactericidal effect, while chloramphenicol binds 
reversibly to the 50S unit and has a bacteriostatic effect [10]. 
 
1.2.3 Drug target - Nucleic acid synthesis 
Nucleic acids, which include DNA and RNA, are genetic material that is essential in all living 
organisms. Antimicrobials can interfere with specific processes in synthesis of nucleic acid at 
several levels. Fluoroquinolones (e.g. ciprofloxacin) interfere with type 2 topoisomerases, 






1.2.4 Drug target - Folate synthesis 
Tetrahydrofolate (THF) is a cofactor involved in the synthesis of DNA, RNA and bacterial cell 
wall proteins [10]. The cellular requirement of folates is universal, but prokaryotes differs 
from mammalian cells in that they commonly lack a transport system for the uptake of folic 
acid from the environment. The bacterial necessity to synthesize folates makes it an 
applicable target for antimicrobials [11]. Trimethoprim and sulphonamides are 
antimicrobials inhibit different enzymes in the biosynthesis of THF and….,respectively [10]. 
  
1.3 Antimicrobial resistance 
Shortly after the introduction and widespread use of antibiotics in the 1940s, there were 
reports of microbial evolution in response to antimicrobial exposure, where the bacteria 
were able to resist the inhibitory effects of the newly discovered drugs. At the end of 
Alexander Flemings Nobel Lecture in 1945, he mentions the danger of antimicrobial misuse- 
"It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them 
to concentrations not sufficient to kill them, and the same thing has occasionally happened in 
the body" [12]. Despite warnings, from both Fleming and other scientists, throughout history 
the inappropriate use of antimicrobials has accelerated bacterial evolution. and made 
Antimicrobial resistance more frequently observed, which complicates the treatment of 
infections [3].  
 
1.3.1 Mechanisms of antimicrobial resistance in bacteria 
Antimicrobial resistance (AMR) can be broadly divided into intrinsic resistance and acquired 
resistance. Intrinsic resistance is a naturally occurring trait due to biological characteristics of 
a microorganism, that make all strains of that species likewise resistant to specific antibiotics 
[13]. Alternatively, acquired resistance may arise in an initially susceptible bacterium, either 
through the acquisition of new genetic material or through mutations to the chromosomal 
DNA [13]. As microbes adapt to their environment random mutations may give them new 
abilities, such as enzymatic modification of antimicrobials, alteration of drug target site, 





reduce the effect of antimicrobial agents [4]. More specific resistance mechanisms will be 
described below for the model organism used in this study, E. coli.   
1.3.1.1 Mutations 
A mutation is caused by a change in the nucleotide sequence of the DNA in an organism’s 
genome. Thus, a mutant will differ from its parental strain in its genotype, the sequence of 
the genome [8]. Depending on the mutation, the observable characteristics of a mutant, its 
phenotype, may or may not differ from its parent. There are several types of mutations 
(discussed below) and their phenotypic effects are highly variable, being neutral, beneficial 
or harmful [8]. Mutations can either be induced or spontaneous; induced mutations arising 
after for example exposure of mutagens, while spontaneous mutations occur without 
external intervention, usually from rare errors made by polymerases during DNA replication 
that are not repaired [8].  
Point mutations are mutations that affect one single base pair. These changes can occur by 
single nucleotide base substitutions in the DNA [8]. Further, these mutations can be divided 
into two subtypes describing the type of base substitution; transition and transversion. 
Transitions are mutations in which one purine base (A or G) substitutes for another purine, 
or one pyrimidine base (C or T) substitutes for another pyrimidine [8]. For transversions, a 
purine base substitutes for a pyrimidine base or vice versa [8]. Point mutations can also arise 
by the loss or gain of a single base pair (deletions or insertions), which lead to a shift in the 
reading frame that will affect the amino acid sequence, likely resulting in alteration of the 
protein function [8]. Deletions and insertions may involve a single base-pair, or result in the 
loss or gain of hundreds or even thousands of base pairs [8].  
There are several functional consequences of point mutations. A silent mutation is defined 
as a mutation that does not affect the phenotype of the cell [8]. Because a silent mutation 
does not lead to alteration in the amino acid sequence, these mutations are also referred to 
as synonymous mutations [8]. When a codon for one amino acid is replaced by a codon for 
another amino acid, it’s called missense mutations [8]. Finally, a nonsense mutation is where 
the codon for one amino acid is replaced by a translation termination (stop) codon [8]. 
Because both missense and nonsense mutations change the protein sequence, they are 





1.3.1.2 Vertical and horizontal gene transfer 
Vertical gene transfer is the transmission of genes from a bacterium to its daughter cells 
during DNA replication and cellular division. AMR mechanisms that are on the genome are 
transferred vertically [8]. However, microorganisms may also acquire resistance genes by 
horizontal gene transfer (HTG); transformation, transduction and conjugation [8].  
Transformation is a genetic process where the lysis of a donor cell causes the release of free 
DNA, which can be taken up by a competent recipient [8]. The recipient may then 
incorporate the foreign DNA into its own genome. This may include AMR genes, making the 
recipient cell resistant as well [8]. 
Transduction involves the transfer of genes by a bacteriophage from one cell to another [8]. 
When a bacteriophage infects a bacterial cell, the enzymes responsible for packaging viral 
DNA into the bacteriophage protein capsid sometimes package part of the host DNA as well 
[8]. Once the bacteriophage host cell is lysed, the bacteriophages can inject their packaged 
genetic material into a new bacterial cell, thus potentially spreading resistance genes [8]. 
Conjugation is a mechanism of genetic transfer mediated by cell-to-cell contact through a 
pilus [8]. The bacterial donor cells transfer copies of mobile genetic elements, such as 
plasmids and transposons, to the recipient, which is then able to maintain them [8].  
 
1.3.2 Fitness – the cost of antimicrobial resistance 
Although the development or acquisition of antimicrobial resistance mechanisms constitutes 
an advantage in favour of the microorganisms, these genetic changes usually cause a 
reduction in growth rate, competitive ability and/or virulence, referred to as a fitness cost 
[14]. Due to the complexity of factors influencing fitness, the precise mechanisms behind 
this phenomenon are not fully understood. However, studies show that the cost of 
resistance is highly variable. Since the genetic mechanisms of resistance often affect 
important biological functions in the cell, they may play a significant role on the fitness of 
the cell. It is also suggested that resistance obtained by chromosomal mutations tends to 







1.4 The Norwegian National Strategy Against Antibiotic Resistance 2015-2020 
From 2005-2012 an increased use of antibiotics in Norway was observed. However, the 
report Drug Consumption in Norway 2012-2016 from March 2017, shows a steady decline in 
the use of antimicrobials [15]. In order to continue this trend, in June 2015 the Norwegian 
Government established a national strategy against AMR that will hopefully reduce the 
unnecessary consumption of antibiotics by 30% by 2020, as measured in DDD/1000 
inhabitant/day, as compared to the 2012 consumption. The major goal of this initiative is to 
be among the top three countries in Europe with the lowest use of antibiotics in humans 
[16].  
In healthcare, around 80% of all antibiotic prescriptions occur in general practice. Due to the 
high volume of antibiotic prescribed in this sector, a great potential exists to reduce the 
consumption of antibiotics, especially when treating respiratory infections in children and 
acute uncomplicated UTIs in women. In hospitals, representing 9% of all prescriptions, the 
increased use of broad spectrum antibiotics appears to be the biggest challenge, as changes 
in resistance patterns cannot explain this rise alone [16]. 
Interventions described in the strategy against AMR focus on various preventative measures 
such as vaccination of the population and hygiene improvements, as well as different efforts 
to better educate prescribers and the general public about antibiotics, which may lead to 
more appropriate use of these drugs. Some of the actions steps mentioned in the strategy 
address issues that are well known to pharmacists. The first involves the mismatch between 
antibiotic packaging and recommended duration of treatment for several antibiotics with 
marketing authorization in Norway. Pivmecillinam (Pivmecillinam®, Selexid®) for example, is 
only used for the treatment of UTIs and, is according to statistics from the Norwegian 
Prescription Database (NorPD) the antibiotic with the second highest numbers of users 
Norway in 2015 [17]. When a standard Pivmecillinam treatment of 200 mg 3 times daily for 3 
days is prescribed, the smallest package of 20 tablets must be dispensed, which result an 
additional 11 tablets being provided to the user. The consequence is the potential for over- 
and misuse of the drug [16]. A similar problem involves the lack of antibiotic drug 
formulations, especially in the treatment of respiratory infections in children. The 





drug and, due to the lack of good alternatives on the market, may lead to the prescription of 
broad-spectrum antibiotics with a better taste. Although narrow-spectrum penicillin is first 
line treatment for respiratory infections, statistics from NorPD shows that 30-50% of 
children are using broad spectrum antibiotics to treat these infections[16] [18]. The last 
issue concerns the 1 year validity of antibiotic prescriptions, which is the same as for other 
prescribed drugs. According to the Institute of Public Health, a large number of prescriptions 
may be dispensed from the pharmacies much later after it was prescribed to patients having 
acute infections [16]. 
 
1.5 Escherichia coli 
The bacterial species Escherichia coli is a rod-shaped, motile Gram-negative in the 
Enterobacteriaceae family [19], and the model organism in this study. This facultative 
anaerobe play a predominant role in the intestinal microbiota of humans and other 
mammals, usually deriving mutual benefits to its host [19, 20]. However, E. coli is a highly 
versatile species, providing the potential to cause a broad spectrum diseases of varying 
severity [20]. Among the most common infections caused by E. coli are urinary tract 
infections (UTIs), diarrheal diseases and bloodstream infections [20]. 
The ability of E. coli to overcome host defenses and colonize in different niches is due to the 
acquisition of specific virulence factors, resulting in pathogenicity. Depending on their site of 
infection, pathogenic E. coli strains can be categorized as intestinal pathogenic E. coli (IPEC) 
or extraintestinal pathogenic E. coli (ExPEC), and are further subdivided into several distinct 
pathotypes [20]. These are groups of strains that among other characteristics, such as 
phylogenetic background and disease manifestation, exhibit unique combinations of certain 
virulence traits.  Example of such virulence attributes are specific adherence factors and 
toxins [20]. 
 
1.6 Biofilms in E. coli 
Bacterial cells may be capable of anchoring to a variety of materials, aggregate, and form 





mode of bacterial life is termed a "biofilm". Biofilm formation allows bacterial cells to remain 
in a convenient niche where they live in close proximity with each other, thus improving 
their likelihood of survival (Brock). 
E. coli biofilms consist of a secreted matrix of polysaccharides called extracellular polymeric 
substances (EPS) [21]. The biofilms in E. coli mainly consists of three exopolysaccharides: 
colonic acid, cellulose and β-1,6-N-acetyl-D-glucosamine polymer (PGA) [21]. The cell-to-cell 
communication within the biofilm occurs via the chemical signaling pathway known as 
quorum sensing (QS); a process where microbes secrete autoinducer (AI) substances to the 
extracellular environment until the required high density is achieved and, thereafter, factors 
affecting biofilm formation and maturation are upregulated [21].  
Biofilm formation provides protection to the bacteria against several factors such as host- 
defense mechanisms, phagocytosis, biocides and hydrodynamic shear forces, as well as 
increasing the bacterial tolerance to antimicrobial agents, hampering their efficacy [21, 22]. 
Besides being the main causative agent for recurrent urinary tract infections, E.coli biofilms 
are also associated with infections related to indwelling medical device-related infectivity, 
such as  urethral and intravascular catheters, prosthetic joints and shunts and grafts, which 
can potentially leading to more serious infections [21]. It is estimated that 65% of human 
bacterial infections involve biofilm formation [23] 
 
1.7 Urinary tract infections 
The urinary tract includes the kidneys, ureters, urinary bladder and the urethra. This organ 
system exhibits various factors that contribute to maintain a sterile environment. These 
defense properties include mechanistic factors, such as regular bladder emptying and urine 
flow, as well as the chemical-defense components of epithelia and, upon bacterial invasion, 
epithelial shedding and influx of effector immune cells [24, 25].  
However, host defense mechanisms are frequently outcompeted by microbial invasion from 
the exterior environment. UTIs arise when microorganisms, especially bacteria, manage to 
colonize within the urinary tract and are among the most common infections in the world 





overrepresented among women due to the anatomic proximity of bowel flora to the short 
urethra. Clinically, UTIs are classified both by the location of the infection in the lower 
(cystitis) or upper (pyelonephritis) urinary tract, and as uncomplicated or complicated. Renal 
disease, diabetes and catheterization are some of the risk factors that may complicate the 
treatment of UTIs, increasing the cost of treatment, morbidity and mortality [27]. 
 
1.7.1 Uropathogenic E. coli  
Although UTIs can be caused by several different pathogens, uropathogenic E. coli (UPEC) 
strains are the most predominant causative agent, and are responsible for 70-95% of 
community acquired UTIs [28]. This pathotype harbors a range of diverse virulence factors 
that contribute to the colonization of the urinary tract, thus causing infection. 
Adhesins, such as Type 1-fimbriae and P fimbriae, are assembled on the surface of the 
bacteria and adhere to receptors of the host urothelial cells. These virulence factors are 
probably the most important determinant in the pathogenicity of UPEC [28, 29]. UPEC may 
also secrete toxins that cause damage of the epithelial cells, such as hemolysin, cytotoxic 
necrotizing factor 1, and autotransporter toxins [29]. Other virulence factors are flagella-
mediated motility, evading host defenses and creating biofilm-like structures of intracellular 
bacterial communities [29]. 
 
1.7.2 Treatment of UTIs 
According to Norwegian guidelines from the Directorate of Health, the recommended first-
line treatment of acute complicated and complicated cases of cystitis are trimethoprim, 
nitrofurantoin and pivmecillinam [30]. Depending on the severity of the infection, whether 
the infection is uncomplicated or complicated, the duration of treatment may vary from 1-3 
days or 5-7 days. Ciprofloxacin and amoxicillin may be suitable drugs of choice in 
complicated cystitis where resistance to conventional treatments is observed [30]. 
According to statistics from the NorPD, pivmecillinam is the most frequently prescribed 
antibiotic for the treatment of UTIs in Norway [17]. The statistics also indicate, as mentioned 





Table 1. Antimicrobials dispensed from pharmacies in Norway. Data from the Norwegian Prescription 
Database from 2011-2015, showing anyone who has had at least one of the listed antibiotics dispensed from a 
Norwegian pharmacy per year. 
 
Drug 
NUMBER OF INDIVIDUALS  
Women (%) 2011 2012 2013 2014 2015 
Mecillinam 189 598 193 934 200 464 203 619 200 771 87 
Trimethoprim 83 347 80 744 76 689 76 400 72 115 85 
Nitrofurantoin 36 784 36 250 36 821 36 878 36 514 85 
 
1.7.3 The ECO∙SENS study – E. coli and UTIs 
The ECO∙SENS studies were conducted in periods between 1999-2000 and 2008-2009, and 
investigated the prevalence of AMR and antimicrobial susceptibility among frequently used 
antimicrobials in uropathogenic E. coli isolates from urinary tract infections (UTIs) in women 
[31, 32]. The isolates used in this study are derived from the ECO-SENS collections. 
The first ECO-SENS study investigated samples from 16 European countries and Canada [31]. 
The second study (ECO∙SENS II) tested isolates from only five selected countries; Austria, 
Greece, Portugal, Sweden and the UK, representing different geographical areas in Europe 
suggested to have more or less frequent antimicrobial resistance [32]. 
ECO∙SENS II confirmed the findings from the first study; where E. coli was the most prevalent 
uropathogen in all of countries. Additionally they found that the consumption and 
emergence of multidrug-resistant bacteria was higher in Southern Europe [32]. Lastly they 
observed a continuing high prevalence of resistance in community uropathogenic E. coli to 
ampicillin, sulfamethoxazole, trimethoprim and sulfamethoxazole/trimethoprim 
combination, while resistance-levels to amoxicillin/clauvanic acid, mecillinam, fosfomycin 
and nitrofurantoin did not show significant increase as compared to the first ECO-SENS study 
[32]. For instance, the prevalence of ciprofloxacin resistance increased from 1,1% (1999-






1.8 Antibacterial agents of interest 
Due to the central roles of mecillinam and ciprofloxacin in the treatment of uncomplicated 
and complicated UTIs respectively, these two drugs were chosen as the main focus in our 
study. Their mechanisms of action and resistance are described in further detail below. 
 
1.8.1 Mecillinam 
Mecillinam, an amdinopenicillin discovered in the 1970s, is an extended-spectrum β-lactam 
antimicrobial showing high specificity to penicillin-binding protein 2 (PBP2) in the Gram-
negative cell wall [33]. Due to its potent antibacterial activity against Enterobacteriaceae, 
especially E. coli, the drug is mainly used in the treatment of uncomplicated UTIs. The 
extensive long-term use in Scandinavian countries shows that mecillinam is a well-tolerated 
drug with a beneficial resistance profile [33]. 
Because of the poor gastrointestinal absorption of mecillinam, the prodrug pivmecillinam 
was introduced to make the drug appropriate for oral administration [34] Enhanced 
lipophilicity and increased bioavailability was possible by introducing an extended double-
ester that masked the polar carboxyl group in mecillinam [35]. This improved the ability of 
the drug to cross hydrophobic cell membranes in the gastrointestinal tract. Once it enters 
the bloodstream, it undergoes enzymatic hydrolysis by ubiquitous esterases that release the 
active antibiotic in the body (Figure 1) [35].Following absorption, high concentrations of 
active mecillinam are excreted in the urine, which according to studies may reach several 
hundred mg/litre during treatment [36]. When it reaches its target site, mecillinam binds to 
and inhibits the transpeptidase activity of PBP2, prevents the cell wall elongation of rod-









Figure 1: Mechanism of pivmecillinam (prodrug) to the active drug mecillinam. 
 
1.8.1.1 Mechanisms of resistance to MEC in E. coli 
Antimicrobial resistance to mecillinam can arise by DNA mutations in a wide range of genes; 
there are at least 38 mutational targets known [37]. These genes are involved in various 
cellular functions in bacteria such as the respiratory chain, cysteine biosynthesis, tRNA 
synthesis, the ribosome and pyrophosphate metabolism [37].  
Since mecillinam is a β-lactam antimicrobial, it can be inactivated by β-lactamase enzymes 
produced by bacteria. These enzymes are hydrolyzing the amide bond in the β-lactam ring 
[38]. The loss or functional change in the outer membrane porins can also result in 
mecillinam resistance. In E. coli, changes in porins such as OmpC, OmpF and PhoE can lead to 





drug target site, PBP2, which is responsible for the elongation of rod-shaped cells. For 
example, some of these mutations are causing elevation of the signal for the stringent 
response, ppGpp, which may render the target of PBP2 [37]. At last, the over-expression of 
efflux-pumps that are pumping the drugs out of the cell can arise, hampering the effect of 
the drug [40]. Example of such pumps are AcrAB-TolC and AcrAD-TolC [40]. 
1.8.2 Ciprofloxacin 
Ciprofloxacin, a member of the quinolone class of antimicrobial agents, is a broad-spectrum 
antimicrobial that has bactericidal activity against both Gram-negative and Gram-positive 
bacteria [41]. As a second generation quinolone, developed in 1981, it differs from the first 
generation quinolones by the introduction of fluorine, piperazine and a cyclopropyl 
substituent in its structure (Figure 2), leading to improved cellular uptake and broad-
spectrum activity, but also reduction of adverse effects [42].  
 Ciprofloxacin interferes with two type 2 topoisomerases, both of which are essential for 
bacterial DNA replication; DNA gyrase and topoisomerase IV. Both enzymes are composed of 
subunits, encoded by gyraA and gyrB (for DNA gyrase) and by parC and parE (for 
topoisomerase IV) [43]. Ciprofloxacin interacts with these enzymes resulting inhibiting their 
activity at the DNA cleavage stage and preventing DNA strands from rejoining after DNA or 
RNA synthesis, which will eventually lead to cell death [43, 44]. The main quinolone targets  
are generally different in Gram-negative and Gram-positive bacteria, where for Gram-
negative bacteria DNA gyrase is the main target, in Gram-positives it is the topoisomerase IV 
[45]. 
 





1.8.2.1 Mechanism of resistance to CIP in E. coli  
Antimicrobial resistance to ciprofloxacin can arise via a combination of mechanisms, such as 
gene mutations causing alterations of the drug target enzymes, decreased membrane 
permeability and/or the production of protein that protect the drug. Ciprofloxacin resistance 
is acquired chromosomal mutations or plasmids [46]. 
Mutations in the genes encoding the two enzyme targets, DNA gyrase and topoisomerase IV, 
are frequently observed in target-mediated ciprofloxacin resistance. The major mutational 
target in E. coli is the DNA gyrase, either gyrA or gyrB. However, mutations in gyrA are more 
commonly observed [43, 45]. These mutations emerge in a DNA-sequence known as the 
quinolone resistance-determining region (QRDR) [43, 45]. In addition, mutations can be 
observed in the subunits parC and parE of topoisomerase IV, but mutations to parE seem to 
have negligible effect [45]. 
Ciprofloxacin resistance can also be acquired by changes in the membrane permeability. This 
can occur due to a decreased expression of porins, such as ompF which regulate influx, as 
well as the overexpression of efflux pumps, for example in SoxRS, regulating both ompF and 
the levels of certain efflux pumps [45]. Another example is chromosomal mutations in the 
MarRAB regulon that can lead to the expression of efflux pump systems, such as AcrAB-TolC. 
Mutations affecting the marR gene induce the constitutive expression of acrAB and tolC, 
leading to the efflux of multiple, diverse drug classes and the development of a multi-
resistance phenotype [43, 45]. Ciprofloxacin resistance can also be acquired from plasmids. 
The qnr gene encodes a protective protein that prevents ciprofloxacin from binding to its 
target [47]. 
 
1.9 Important definitions in describing antimicrobial susceptibility 
The performance of antimicrobial susceptibility testing (AST) is one of the most important 
tasks in clinical microbiology laboratories. Various techniques of in vitro susceptibility testing 
can be used to assess the susceptibility of microorganisms to certain antimicrobials, which is 





There are different ways to perform AST, but the most well-known methods include broth 
dilution and antimicrobial diffusion assays. The broth dilution method, representing the gold 
standard of AST, is usually performed by adding bacterial inoculum to a 96 well plate 
containing a predetermined concentration of antimicrobials diluted in MH-broth [48]. 
Antimicrobial diffusion assays are performed by applying a gradient strip or a disk, 
impregnated with the antimicrobial at known concentrations, to an inoculated agar plate. 
After incubation, the zone of inhibition can be used to determine the susceptibility of the 
microorganisms [48].  
AST is an essential part of this project. The gradient strip method was used to determine the 
minimum inhibitory concentration (MIC), defined as the lowest concentration of an 
antimicrobial drug required to inhibit the visible growth of a microorganism, thus confirming 
resistance to ciprofloxacin and/or mecillinam. The microbroth dilution method was used to 
determine the 90% inhibition value (IC90) and describe collateral sensitivity and collateral 
resistance networks for the isolates.  
1.9.1 EUCAST – Clinical breakpoints 
To determine whether antimicrobial therapy will be successful or not, AST results require 
interpretive criteria to define the tested isolates as susceptible, intermediate or resistant. 
The European Committee on Antimicrobial Susceptibility testing (EUCAST), established in 
1997, publishing clinical breakpoints with yearly updates to standardize the breakpoints 
across Europe [49]. These breakpoints are also used to confirm resistance in the mutants 
generated in this study. 
 
 
 1.10 Collateral sensitivity – a new strategy to combat AMR 
Improvement of antibiotic treatment strategies is of utmost importance to prevent the 
development of resistance and preserve the efficacy of antimicrobial agents. One possible 
approach may be to take advantage of a side-effect in the evolution of antimicrobial 





Szybalski and Bryson first describes this phenomenon in a report investigating cross-
resistance (CR). In addition to their expected observations of CR, they also observed the 
reverse phenomenon where bacteria acquiring resistance to one antimicrobial drug 
simultaneously became more sensitive to others, which they named CS [7]. Further 
investigations of CS have been absent until recently; when in 2013 Imamovic and Sommer 
published a similar study investigating changes in susceptibility due to AMR development 
[1]. They evolved resistance in E. coli to 23 clinically-relevant drugs and mapped the resulting 
network of CS and CR changes to each drug. Based on reciprocal CS the authors proposed a 
cycling scheme - collateral sensitivity cycling. The idea behind this drug cycling is to suppress 
the emergence of resistant bacteria and be able to reintroduce antimicrobials in the cycle, 
thereby increasing their life-span [1].  
 
 
A schematic of collateral sensitivity cycling is shown in Figure 3. At the start (t0), a sensitive, 
pathogenic WT cell population (black circles) is exposed to treatment with drug A. After a 
given time of exposure, the population will develop resistance (orange circles) and the drug 
becomes ineffective (t1). Following resistance development to drug A, the bacteria become 
collaterally sensitive to drug B. By switching treatment to drug B, the resistant bacteria are 
Figure 3: Collateral drug cycling. Model describing the main idea of collateral drug cycling. Adapted and 





killed at a higher rate than the WT population, who’s sensitivity to drug A and B has not 
changed (t2). Resistance to drug B (green circles) will then emerge (t3), and treatment is then 
switched back to the initial treatment of drug A, to which drug B-resistant cells show 
collaterally sensitivity. The main idea is that the strain will be recycled back to its original 
sensitive phenotype. 
 
1.10.1 Research focus of the MicroPop Research Group 
In the MicroPop research group, collateral sensitivity profiles have previously been mapped 
for ten E. coli isolates resistant to mecillinam or ciprofloxacin, as shown in Figure 4 and 
Figure 5 (Podnecky et al., unpublished results).  The red color represents increases in 
resistance, while the blue color represents increases in sensitivity.  
For the ciprofloxacin-resistant mutants CR effects were more frequent than CS. However, CS 
observed in most isolates to the aminoglycoside gentamicin, as well as fosfomycin. Another 
interesting observation is the variation between the strains. While K56-78 has a lot of cross 
resistance, K56-2 strain show almost no changes in susceptibility at all.  
In the mecillinam resistant mutants, there are much less trends and changes in susceptibility 
being observed. However, more collateral sensitivity and neutrals are seen compared to the 
ciprofloxacin mutants. The exception is for azithromycin, where almost all of the strains 
shows collateral sensitivity.  
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2 AIMS AND HYPOTHESIS 
  
2.1 Aims 
Our aim in this project is to investigate the generality of collateral sensitivity and collateral 
resistance in clinical urinary tract isolates of E. coli made resistant to mecillinam and/or 
ciprofloxacin, two important drugs in the treatment of UTIs. The results are mapped in 
heatmaps and compared to earlier observations in the MicroPop research group and the 
literature. In addition, we will investigate effects of the mutations on biofilm forming ability 
of the resistant mutants. 
 
2.2. Hypothesis 
Our main hypothesis is that collateral sensitivity networks exist on a population level. We 
hypothesize that we will see more cross-resistance in ciprofloxacin resistant mutants than 
collateral sensitivity. For the mecillinam resistant mutants we hypothesize to see more 
collateral sensitivity. For the isolates evolved resistant to both drugs, we hypothesize that 
the presence of more than one resistance determinant will affect the CS network.  
Additionally, we hypothesize that some of the resistance mechanisms might interfere with 
the biofilm forming abilities of the mutants. 
 
 








3 MATERIALS AND METHODS 
 
3.1 Bacterial strains 
The bacterial strains used for generating MEC- and/or CIP-resistant mutants are listed in 
Table 2.  Clinical isolates of E. coli from the ECO∙SENS strain collection are used in this study. 
The chosen isolates are pansusceptible, meaning that they are not resistant to commonly 
tested antimicrobials for E. coli (ECO-SENS) and are plasmid-free isolates [32]. Additionally, 
the control strains ATCC 25922 and ATCC 35984 were used for AST and the biofilm assay, 
respectively. 
Table 2. E. coli UTI isolates used in this study 
Strains Sequence type Phylogroup Country of origin Year 
K56-22 73 B2 Sweden 2000 
K56-23 73 B2 Sweden 2000 
K56-24 73 B2 Sweden 2000 
K56-25 73 B2 Sweden 2000 
K56-26 73 B2 Sweden 2000 
K56-29 73 B2 Sweden 2000 
K56-30 1161 B2 Sweden 2000 
K56-35 73 B2 UK 2000 
K56-38 73 B2 UK 2000 
K56-46 73 B2 Greece 2007-2008 
K56-63 135 B2 Sweden 2007-2008 
K56-67 141 B2 Sweden 2007-2008 
K56-73 73 B2 UK 2007-2008 
K56-76 976 B2 UK 2007-2008 
K56-77 1236 B2 UK 2007-2008 
K56-80 141 B2 UK 2007-2008 
 
 




3.2 Growth media 
The use of growth media is essential to facilitate good environmental and nutritional growth 
conditions for the bacteria. Cultivation of bacteria were accomplished in both liquid- and 
solid media in this project.  
 
3.2.1 Luria-Bertani (LB) medium 
Luria-Bertani (LB) broth is a nutritionally rich media commonly used for the growth and 
maintenance of E. coli strains. Bacteria were cultivated in either liquid or solid media 
prepared in the MicroPop laboratory as specified by the manufacturer. 
LB broth: 
Mix 20 g LB broth (BD Difco ™, Miller) with 800 ml dH2O and autoclave at 121°C. The 
medium is cooled and then stored at 4°C. 
LB agar (LBA): 
Mix 20 g LB broth (BD Difco ™, Miller) and 12 g Select agar (Sigma-Aldrich) with 800 mL dH2O 
and autoclave at 121°C. The medium is cooled to 50-60°C and poured into sterile petri 
dishes. The agar plates are drying overnight and stored at 4°C. 
 
3.2.2 Mueller-Hinton (MH) medium 
Cation-adjusted Mueller-Hinton II (MH) broth is a growth medium that is widely used for 
AST. MH agar plates were prepared in the laboratory as specified by the manufacturer, while 
MH broth was obtained from the University Hospital of Northern Norway (UNN) in Tromsø. 
MH II agar (MHA): 
Mix 30,4 g of MH II agar (Sigma-Aldrich) with 800 mL dH2O and autoclave at 121°C. The 
medium is cooled to 50-60°C and poured into sterile petri dishes. The agar plates are left to 
solidify overnight and stored at 4°C. 




3.2.3 Tryptic Soy Broth (TSB) medium and TSB with glucose 
Tryptic soy broth is a nutrition rich medium used for the determination of biofilm formation 
in this project. TSB and TSB with 1% glucose were obtained from the University Hospital of 
Northern Norway (UNN) in Tromsø. 
 
3.2.4 Other solutions and reagents 
 
0,85% saline: 
Add 0,65 g of sodium chloride (≥99,5%, Fluka) into 80 ml dH2O. Autoclave at 121°C and store 
the solution at room temperature.  
80% glycerol: 
Add 54 ml of a glycerol solution (86-89% purity, T) (Sigma-Aldrich) into a 100 ml graduated 
cylinder and adjust with dH2O to 100 ml in total volume. Autoclave at 121°C and store the 
solution at room temperature. 
70% ethanol: 
Add 70 ml of 96% to 30 ml of dH2O. 
Matrix Solution for MALDI-TOF: 
Stock solution: add 475 µl of MilliQ-water into a tube, then add 500 µl acetonitrile and 25 µl 
trifluoracetic acid. Mix vortexing. The solution is then aliquoted into 1,5 ml tubes and store 
cool. 
Add 250 µl of the stock solution to a HCCA-tube. Vortex for 1 minute until the solution is 
completely transparent. Protect from light during storage. 
TFA for MALDI-TOF: 
Add 50 µl of dH2O and 200 µl of 100% TFA in an Eppendorf tube. Shake for 1 minute. 
 




3.3 Bacterial cultivation 
Different techniques were used to cultivate bacteria in this study. Depending on the purpose 
for the cultivation, bacteria were either cultured in liquid or solid medium, as described 
below.  
 
3.3.1 Overnight cultures  
 
Overnight cultures were made by inoculating a pure isolated colony of bacteria from an agar 
plate into 5 ml of LB. The solution is then incubated under conditions that will support 
growth, 37°C for E. coli, shaking at approximately 225 rpm. 
 
3.3.2 Plating techniques on solid medium 
Three different plating methods were used to achieve desired growth of bacteria on solid 
medium. This was done in a petri dish containing an appropriate growth medium with agar 
as a solidifying agent. 
 
3.3.2.1 Streak for isolation technique 
The 3-zone streaking technique is used to achieve the growth of pure isolated colonies. By 
spreading the bacterial inoculum across different areas of the plate, single colonies are 
observed at end of the streak were the bacteria is spread thinly.  
Start by using a sterile loop and pick the inoculum from an agar plate, liquid medium or a 
freeze stock culture. Then streak the inoculum in zone 1 by moving the loop back and forth, 
in a zigzag-pattern, down the first third of the agar plate. Following the initial streak, use a 
new sterile loop and streak the next third of the plate by dragging a few lines from zone 1 
into zone 2. Continue with the same loop and drag a few lines from zone 2 to zone 3. 








Figure 6: Demonstration of streak for isolation technique. 
 
 
3.3.2.2 Spread plating 
Plating with sterile glass beads is an easy technique to achieve evenly spreading of a 
bacterial liquid culture on the entire growth surface of an agar plate. Around 20 sterile glass 
beads are poured onto the plate together with the liquid culture. Shake the plate(s) in a 
horizontal plane until the inoculum is completely absorbed. The glass beads are then 
collected into a waste container for decontamination and sterilization when the plate is dry.  
 




3.3.2.3 Swab plating 
This technique is performed by using an electrically driven rotator that spins with a constant 
speed to achieve uniform plating of the inoculum on agar plates.  




Start by putting a sterile cotton swab in a 0,5 McFarland solution, and removing excess liquid 
by pressing the swab on the inside of the glass tube. Place the agar plate on the rotator. 
Start inoculation by placing the swab gently on the edge of the plate, and then slowly move 
the swab into the centre. Then, twist so that a new side of the swab is in contact with the 
agar and start moving the slowly back to the initial point. 
 
Figure 8: Demonstration of swab plating technique. 
 
 
3.4 Other standard microbiology techniques 
 
3.4.1 McFarland standard 
McFarland standards are made by adjusting the turbidity of bacterial cells in a suspension, 
ensuring that the number of bacteria will be within a certain range. A 0,5 McFarland 
suspension (6x108 CFU/ml), used for AST in this project, was prepared by suspending a small 
number of isolated colonies from an agar plate into a glass tube containing 0,85% NaCl. The 
correct turbidity is determined by measuring the optical density of the suspension in a 
calibrated densitometer. 
 
3.4.2 Storage in freeze stock cultures 
A freeze stock culture (stored at -80°C) is made to allow long-term storage of bacterial 
strains. The freeze stock is prepared by adding 250 µl of 80% glycerol as a cryoprotecting 
agent together with 750 µl of an overnight culture into freeze tubes.  




3.5 Generation of antimicrobial resistant mutants 
Antimicrobial resistant isolates of E. coli with reduced susceptibility to ciprofloxacin or 
mecillinam were generated by static selection under antimicrobial pressure. The protocol 
was adapted for each of the two drugs to acquire clinically resistant mutants for each 
antimicrobial. However, while the MEC mutants are generated in the laboratory after one 
single step, the CIP mutants needed to be exposed to a gradually increasing antimicrobial 
concentration before reaching clinically resistant levels. 
Moreover, in addition to the selection of mutants with either resistant to mecillinam or 
ciprofloxacin resistance alone, clinically resistant isolates made resistant to both 
antimicrobials were also generated. This procedure was performed by using the same 
methods as for the single-mutants. Using the same strains, the double-mutants were 
acquired by making MEC mutants resistant to ciprofloxacin, as well as CIP mutants made 
resistant to mecillinam.  
All the mutants generated were used for the IC90-testing to investigate CS and CR to specific 
antimicrobial agents, described more in detail in Section 3.8. 
 
3.5.1 Mecillinam resistant mutants 
 
3.5.1.1 Mecillinam stock solution 
Mecillinam stock solutions were made to a final concentration of 1 mg/ml to make MHA 
MEC plates. To prepare the solution, 100 mg of mecillinam powder (Sigma-Aldrich) was 
dissolved in 100 ml of ddH2O. The suspension was sterile filtered using a 0,2 µM filter unit, 
and then 4 ml volumes was aliquoted into cryovials and stored at -25°C. 
 
3.5.1.2 Preparation of mecillinam selective plates 
Selective plates containing 16 µg/ml mecillinam were used to acquire resistant mutants from 
wild-type strains. However, when making CIP resistant mutants resistant to mecillinam, 
plates containing 8 µg/ml were also used.  




As specified by the manufacturer, a solution of 400 ml MH II agar were prepared by mixing 
15,2 g of MHA II with 400 ml of dH2O, before autoclaving at 121°C. The medium was then 
cooled to 50-60°C and mecillinam stock solution was added into the MH broth to the desired 
final concentration (Table 3). The agar plates were then poured and left to solidify overnight. 
Plates were stored at 4°C for maximum of one week.  
Table 3. MEC selective plates 
MHA MEC plate MEC8 MEC16 
Concentration of MEC 
Stock (mg/ml) 
1 1 
Volume of MEC added to 




3.5.1.3 Method – Static antimicrobial resistance selection 
 
Preparation of selection inoculum: 
1. Grow isolate(s) of interest by scraping a small sample of a freeze stock and streak for 
isolation on LB plate(s) (see Section 3.3.2.1). Incubate overnight at 37°C. 
2. Pick an isolated colony and inoculate it into 5 ml LB media in a sterile tube. Incubate 
the overnight culture at 37°C with shaking at 225 rpm. 
Selecting mecillinam resistant mutants using selective plates: 
3. 100 µl of the overnight culture is plated with glass beads onto MHA-Mec16 plates (see 
Section 3.3.2.2). 
4. 100 µl of the overnight culture is also added into the first well of a sterile 96-well 
plate and serially diluted (1:10 dilutions) in 0,85% saline to a final dilution factor of 
10-6/10-7 as shown in Table 3.  Each dilution is mixed well by pipetting 10-20 times. 
Then 100 µl of the 6th and 7th dilutions are plated with glass beads to achieve 
countable colonies on non-selective LBA plates. 
5. After overnight incubation, or up to 48 hours, visible colonies on selective MHA-
MEC16 plates and non-selective LB plates are counted to determine the mutation 
frequency rate (see Section 3.5.3).  
 




Purification and storage of mecillinam resistant mutants: 
6. Pick a single colony from the selective plate and streak for isolation on a new MHA 
MEC16 plate. Incubate overnight at 37°C. 
I. If there are no single colonies, touch a selection of colonies and streak on a 
new selective plate to achieve single colonies. 
II. Using one plate per colony, streak at least 3 colonies of different appearances 
for isolation. Make note of phenotypes. 
7. Pick well-isolated single colonies using a sterile loop and inoculate into 5 ml of LB. 
Incubate overnight at 37°C shaking 225 rpm.  
8. Make freeze stocks of the overnight culture in 20% glycerol and store at -80°C. 
 
 
3.5.2 Ciprofloxacin resistant mutants 
 
3.5.2.1 Ciprofloxacin stock solution 
Ciprofloxacin stock solutions were made to a final concentration of 25 mg/ml. The stock was 
used to make MHA CIP plates and overnight cultures. The solution was prepared by 
dissolving 50 mg of the ciprofloxacin powder in 2 ml of 0,1 HCl. The suspension was filter 
sterilized using a 0,2 µM filter unit, aliquoted into sterile tubes and stored at -25°C. 
  
3.5.2.2 Preparation of ciprofloxacin selective plates 
To achieve bacterial strains resistant to ciprofloxacin, selective media of different 
concentrations were used. 
As specified by the manufacturer, a solution of 400 ml MH II agar were prepared by mixing 
15,2 g of MHA II with 400 ml of dH2O, before autoclaving at 121°C. The medium was then 
cooled to 50-60°C and appropriate volumes of the ciprofloxacin stock solution was added 
into the MH broth to the desired final concentration (Table 4). The agar plates were poured 
the agar plates and left to solidify overnight. The plates were stored at 4°C for a maximum 
one week. 
 




Table 4. Volume of CIP added in 400 ml MH II to make selective plates of various concentrations. 
MHA CIP plate CIP 0,016 CIP 0,032 CIP 0,064 CIP0,128 CIP0,25 CIP0,5 CIP1 CIP2 
Concentration of CIP 
Stock (µg/ml) 
0,016 0,032 0,064 0,128 0,25 0,5 1 2 
Volume of CIP added 
to 400 ml of MH agar 
(µl) 
0,256 0,512 1,024 2,048 4 8 16 32 
 
3.5.2.3 Method – Stepwise static antimicrobial selection 
Preparation of selection inoculum: 
1. Grow isolate(s) of interest by scraping a small sample of a freeze stock and streak for 
isolation (see Section 3.3.2.1) on LB plate(s). Incubate overnight at 37°C. 
2. Pick an isolated colony and inoculate it into 25 ml LB media in a sterile 100 ml flask. 
Incubate the overnight culture at 37°C with shaking at 150 rpm. 
 
Selecting ciprofloxacin resistant mutants using selective plates: 
3. Pipet 10 ml of the overnight culture into a sterile 15 ml conical tube and pellet the 
culture by centrifuging at 4000 rpm for 10 minutes at room temperature (20°C). 
Decant the supernatant into a waste bottle and resuspend the cell pellet in 1 ml of LB 
medium by pipetting thoroughly so that the dilutions and cell concentration 
calculations will be accurate. Pipet 100 µl of the resuspended pellet onto MHA CIP 
selective plates and spread the inoculum with glass beads (see Section 3.3.2.2). 
4. 100 µl of the resuspended pellet was also added into the first well of a sterile 96-well 
plate and serially diluted in saline to a final dilution factor of 10-7/10-8 as shown in 
Table. Mix well by pipetting 10-20 times. 100 µl of the 7th and 8th dilutions were 
plated with glass beads to achieve countable colonies on non-selective LBA plates. 
Selective- and non-selective plates are incubated overnight at 37°C.  
5. After overnight incubation, or up to 48 hours, visible colonies on selective MHA-CIP 
plates and non-selective LBA plates are counted to determine the mutation 
frequency rate (see Section 3.5.3). 




6. If growth is not present on selective plates above the clinical breakpoint, a mixture of 
colonies from the highest concentration plate with growth is used to inoculate a new 
flask with 25 ml MH medium containing the corresponding CIP concentration.  
 
The process is then repeated from step 3 to 6 with increasing concentrations of CIP selection 
until growth on MHA with CIP at 1 or 2 µg/ml is observed. 
 
Purification and storage of ciprofloxacin resistant mutants: 
7. Pick a single colony from MHA CIP1 or CIP2 and streak for isolation on a new MHA 
CIP2 plate. Incubate overnight at 37°C. 
III. If there are no single colonies, touch a selection of colonies and streak for 
isolation on a new selective plate to achieve single colonies. 
IV. Using one plate per colony, streak at least 3 colonies of different appearances 
for isolation to have a selection of isolates. Make note of phenotypes. 
8. Pick well-isolated single colonies using a sterile loop and inoculate them into 5 ml of 
LB. Incubate overnight at 37°C shaking 225 rpm.  
9. Make freeze stocks of the overnight culture in 20% glycerol and store at -80°C. 
 
3.5.3 Mutation frequency 
To determine the total number of bacteria plated from the overnight culture or the re-
suspended pellet, the dilution factor is multiplied with the number of counted colonies on 
the non-selective dilution plate: 
 





The mutation frequency can then be calculated: 
 
Mutation frequency =











3.6 Identification of E. coli by MALDI-TOF 
Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) mass spectrometry 
(MS) is a versatile analytical technique used to detect and characterize organic molecules 
[50]. This identification system has become a useful tool within microbiology in recent years 
due to its rapid, sensitive and inexpensive identification of different microorganisms. 
In MALDI, the sample to be analysed is shot with laser pulses causing thermal desorption 
and ionization of highly abundant microbial proteins. Singly protonated ions are accelerated, 
based on their mass-to-charge ratio (m/z), into a time-of-flight (TOF) mass analyser. A 
detector, measuring the time a particle require to travel the length of the flight tube, 
generates a characteristic mass spectrum of the sample. The MALDI Biotyper software 
compares the resulting mass spectrum to a known database of different microorganisms, 
thus identifying the bacterial species by its "fingerprint". In this way, we can confirm that the 
selected mutants in this study are truly E. coli [50]. 
3.7.1 Cleaning the 96-well target plate 
1. Place the target plate into an empty petri dish and add enough 70% EtOH to 
submerge the plate. Incubate for 5 minutes. 
2. Rinse the plate with distilled water and wipe with absorbent tissue moistened with 
70% EtOH. 
3. Rinse again with distilled water and dry the plate on absorbent tissue. 
4. Add 100 µl of 80% TFA onto the target plate and clean every well with absorbent 
tissue. 
5. Finish by cleaning the target plate by rinsing with distilled water. 
 
3.7.2 Direct transfer of bacterial colonies to target plate 
1. Resistant mutants are struck for isolation on LBA plates (see Section 3.3.2.1) and 
incubated at 37°C overnight. 
2. Using a wooden stick, a single isolated colony is picked from the LBA plate and 
transferred to a selected well on the target plate. The bacteria sample is spread 
evenly within the well creating a thin layer.  




3. When all samples are applied to the target plate, then 1 µl of matrix are added to 
each well. When dried matrix crystallizes, the inoculated target plate is ready to be 
analyzed. 
 
3.7.3 Analysis and results 
- A score over 2.000 represents accurate identification at the species level. 
- A score between 1.700-1.999 indicates a non-reliable identification of species, but 
accurate identification at the genus level. 
- A score under 1.700 indicates no reliable identification. 
 
3.7 Minimum inhibitory concentration testing by diffusion strips 
To confirm antimicrobial resistance in the generated mutants, antimicrobial gradient 
diffusion strips were used to determine MIC values. These strips are made of porous paper 
impregnated with a predefined concentration gradient of antibiotic on one side, across 15 
two-fold dilutions, while the other side has a MIC scale in µg/ml and a code representing the 
antimicrobial drug for use during result interpretation.  
When the MIC-test strip is applied on an inoculated agar plate, the antibiotic immediately 
diffuses out into the agar. After incubation for 16-20 hours, either no inhibition or an 
elliptical inhibition zone centred along the strip will be observed. The MIC value is read 
directly from the scale at the edge of the elliptical inhibition zone. With any antimicrobial, 
the growth on one side of the strip growth may be higher than the other side; the highest 
value is used as the MIC. 
Method: 
1. Streak the mutants of interest for isolation onto non-selective MHA plates (see 
Section 3.3.2.1) and incubate overnight at 37°C. 
2. Use a sterile cotton swab to pick up a small amount of the isolated colonies from the 
MHA plate. Twist the swab around on the plate to achieve an even and thin layer of 
bacteria on the swab. 




3. Suspend the colonies in a glass tube containing 0.85% NaCl to an optical density of 
0.5 McFarland. Adjust the suspension by adding more bacteria or saline if necessary. 
4. Within 15 minutes, put a new cotton swab into the suspension, remove excess liquid 
by pressing it to the inside of the glass tube and inoculate the agar plate using the 
swabbing for confluency method (see Section 3.3.2.3). Let the plate dry for 
maximum 15 minutes. 
5. Sterilize tweezers using 70% EtOH and a gas flame, then apply the MIC-strip to the 
agar plate. Gently press the strip to the agar without moving it after application.   
6. Put the plate(s) in the incubator within 15 minutes after the strip is applied. Incubate 
the plate(s) at 37°C for 16-20 hours. 
The MICs are interpreted using the EUCAST clinical breakpoint, shown in Table 5. 
Table 5. EUCAST Clinical Breakpoints. 
 Ciprofloxacin Mecillinam 
EUCAST Clinical breakpoints 
Sensitive (S) ≤ 0,5 
Resistant (R) > 1 
Sensitive (S) ≤ 8 




3.8 IC90 antimicrobial susceptibility testing 
The inhibition concentration-90 (IC90) value, defined as the lowest concentration of the drug 
that inhibits at least 90% of the growth of a tested isolate, is used to determine the 
antimicrobial susceptibilities. Changes in the susceptibility (collateral sensitivity) or 
resistance (cross-resistance) were investigated with 6 selected antimicrobials (Table) by 
initially performing a 2-fold dilution, followed by a 1,5-fold dilution based testing to achieve 
a more precise result. 
 
Table 6. Antimicrobial agents used in this study. 
Antimicrobial Antimicrobial class Antimicrobial target 
Azithromycin Macrolide Protein synthesis (50S ribosome unit) 
Chloramphenicol Other class Protein synthesis (50S ribosome unit) 
Ciprofloxacin Fluoroquinolone DNA-replication (DNA gyrase and topoisomerase IV) 




Gentamicin Aminoglycoside Protein synthesis (30S and 50S ribosome subunits) 
Mecillinam Extended spectrum          
β-lactam 
Cell wall synthesis (PBP-2) 
Trimethoprim Antifolate Folic acid synthesis (DHFR) 
 
Procedure: 
1. Isolates of interest, as well as an E. coli control strain (ATCC 25922), were struck for 
isolation on LBA plates (see Section 3.3.2.1) and incubated at 37°C overnight.  
2. The 96-well plate(s) are prepared by loading MH broth into the wells, depending on 
which dilutions series being tested, as shown in Table 7 and Table 8. 
 
Table 7. 2-fold dilution 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
B 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
C 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
D 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
E 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
F 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
G 100 µL  100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
H             
 
Table 8. 1,5-fold dilution 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
B 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
C 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
D 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
E 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
F 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
G 100 µL  50 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 100 µL 
H             
 




3. The working stock of the antimicrobial is diluted in MH broth to 2x the highest tested 
concentration. To ensure that correct antimicrobial stock solution is made, the 
specific MIC-testing guidelines and/or manufacturer's guidelines are followed. 
4. For 2-fold dilutions, 200 µl of the antimicrobial working stock is added in column 2. 
For 1,5-dilutions, 200 µl of the antimicrobial working stock is added in column 2, as 
well as 150 µl into column 3.  
 
5. For 2-fold, 100 µl is taken from column 2 to column 3, and then mixed by pipetting 
10-15 times. The drug is serially diluted across the plate, and 100 µl of the mixture is 
discarded at the end from column 11.  
 
For 1,5-fold, 100 µl is taken from column 2 to column 4, and then mixed by pipetting 
10-15 times. Continue to mix and serially dilute the antibiotic in every second column 
(even numbered columns), and discard 100 µl of the mixture in the end from column 
10. Furthermore, 100 µl is taken from column 3 to column 5, and then mixed by 
pipetting 10-15 times. Continue to mix and serially dilute the antibiotic in every 
second column (odd numbered columns), and discard 100 µl of the mixture in the 
end of column 11.  
 
6. Prepare a 0,5 McFarland in 0,85% sterile saline from each strain by picking up a few 
isolated colonies from the LBA plates. 
7. The 0,5 McFarland is diluted 1:1000 by adding 5 µl into 4,995 ml MH broth and mixed 
by inverting the tube. 
8. Finally, 100 µl of the diluted McFarland is added into wells in columns 1-11.  
9. The 96-well plate is incubated at 37°C for 18 hours with shaking at 700 rpm.  
10. After 18 hours of incubation the OD600nm was measured in a plate reader.  
The OD600nm measurements of the sample with different antimicrobial concentrations, as 
well as the positive and negative controls, were used to calculate the IC90: 
 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = (1 −
(OD600 drug 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 −  OD600 negative control)
(OD600 positive control −  OD600 negative control)
)  𝑥 100 
 




Table 9. Equipment used in the IC90 assay. 
Equipment Producer 
Microplater Shaker TiMix 5 control Edmund Büler GmbH 
VersaMax ELISA Microplate Reader Molecular devices 
 
 
3.9 Determination of biofilm formation 
 
Procedure: 
1. Streak the strains of interest onto MHA plates and incubate overnight at 37°C. 
2. Inoculate a single colony from the MHA plates into 5 ml TSB and incubate overnight 
at 37°C with shaking at 220 rpm.  
3. The overnight culture is diluted 1:100 in fresh TSB supplemented with 1% glucose, 
adding 30 µl culture into 3 ml TSB with 1% glucose. 
4. For each strain, 150 µl of the bacterial suspension is added into a column of a 96-well 
polystyrene tissue culture plate (Thermo Fisher Scientific), including positive control 
strain RP62A and negative blank control. 
The plate is incubated for 24 hours at 37°C without shaking.  
 
5. Remove the liquid cultures by pipetting and wash the plate gently by pipetting 
distilled water in and out of the wells three times. 
6. Leave the plate at room temperature overnight or in an incubator at 55°C for one 1 
hour to dry the plate. 
7. Add 200 µl of crystal violet in each well to stain the biofilm. Incubate for 5 minutes. 
8. Wash the wells gently with tap water in the sink.  
9. Add 200 µl of EtOH in each well and measure the OD of the adherent biofilm in a 
plate reader at 570 nm.  
10. These experiments must be done in a minimum three parallels.  
 
 





11. Before calculating the average value its necessary to avoid the effect that extreme 
low or extreme high observations will have on the average. The outliers are therefore 
removed from the data. The average value is calculated for each parallel: 
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 =

















4 EXPERIMENTAL RESULTS 
 
In this study, we wanted to investigate CS and CR effects in clinical E. coli strains from UTIs of 
different genetic backgrounds. Isolates clinically resistant to mecillinam and ciprofloxacin, 
two important drugs in the treatment of UTIs, were generated. Additionally, we wanted to 
see whether the mutations can affect the biofilm forming ability of the resistant mutants. 
 
4.1 Isolation of clinically resistant mecillinam isolates 
In this project, mecillinam resistant isolates were generated from eight clinical strains 
selected from the ECO-SENS collections. The aim was to obtain resistant isolates with MICs 
above 8 µg/ml, the clinical breakpoint for mecillinam. Visible growth on selective plates with 
16 µg/ml were observed after one single selection step for all the strains, after incubation 
for one or two days. From each strain, resistant isolates were generated and purified and 3-5 
single colonies were stored. 
To determine MIC values and confirm clinical resistance to mecillinam, antimicrobial 
gradient diffusion strips were used. The isolates that were successfully purified and classified 
as clinically resistant, are listed in Table 10. The MIC value was interpreted by reading the 
concentration directly of the strip. The MIC interpretation was sometimes challenging for 
the mecillinam mutants, as spontaneous mutants with even higher mecillinam MICs were 
frequently observed within the zone of inhibition. MIC determination for ciprofloxacin was 
also performed to detect any cross-resistance to this drug. 
 
Table 10: E. coli strains successfully purified and made clinically resistant to mecillinam. 










K56-30 3,24x10-8 IV 0,016 32 
K56-35 2,05x10-8 V 0,032 8-12 











K56-76 2,15x10-7 I 0,016 8 
K56-77 9,5x10-8 I 0,023 24 
K56-80 1,06x10-7 III 0,012 24-32 
 
As well as generating mecillinam resistant isolates by static selection, some strains from the 
ECO-SENS collection were already selected for mecillinam resistant mutants in the MicroPop 
laboratory, but had to be confirmed clinically resistant by MIC-testing and E. coli by MALDI-
TOF. These isolates, displayed in Table 11, was also used in the project. 
Table 11: MEC resistant isolates generated in the MicroPop research group. 
Parental strain MIC CIP (µg/ml) MIC MEC (µg/ml) 
K56-22 0,032 48 
K56-26 0,023 24 
K56-29 0,047 64 
K56-38 0,012 16 
K56-46 0,023 12-16 
K56-63 0,047 ≥256 
These were generated in the MicroPop group by Elizabeth Aarag Fredheim. 
 
During the static selection process, the K56-49, K56-51 and K56-61 strains stood out from 
the rest. Generating mecillinam resistant mutants with these strains was attempted twice, 
however the colonies had variable morphologies both in size and shape, and a homogenous 
colony phenotype was not achieved in any of the strains after trying to purify them. These 
strains were therefore excluded from the project. Similar observations of different 
morphological types and sizes were also seen in other strains, but typically one or more of 
the resulting mutants were successfully purified. In addition, slow growing and 
contaminated isolates were also observed, and the isolates were then excluded. 
 
The mutation frequency rate was the highest for strain K56-73 (2,15x10-7), and the lowest 





K56-63 and K56-73 which were over the detection limit of the strip (≥256 µg/ml), and the 
lowest for strain K56-76 (8 µg/ml), respectively. All isolates were identified as E. coli by 
MALDI-TOF, except from one case where several isolates derived from strain K56-51 were 
identified as Stapholycoccus saprophyticus. These were obviously contaminants and were 
excluded from the study. 
 
4.2 Isolation of clinically resistant ciprofloxacin isolates 
In addition to the mecillinam mutants, ciprofloxacin resistant isolates were generated from 
six strains selected from the ECO-SENS collections. By exposing the strains to a progressively 
increasing antimicrobial concentration, resistant isolates with MIC above 1 µg/ml, the 
clinical breakpoint for ciprofloxacin, were obtained. Resistant isolates were generated 
requiring 2-3 antimicrobial selection steps and multiple mutants were purified for each 
strain (3-5 single colonies). 
 
As was done for the mecillinam mutants, antimicrobial gradient diffusion strips were used to 
determine MIC values and confirm resistance to ciprofloxacin. The isolates that were 
purified and successfully classified as clinically resistant are listed in Table 12. MIC 
determination for mecillinam was also performed to detect any cross-resistance to this drug. 
 
Table 12: E. coli strains successfully purified and made clinically resistant to ciprofloxacin. 


























































































ND: Mutation frequency not determined due to dense growth on selection plate. 
 
 
Two ciprofloxacin resistant isolates from the MicroPop laboratory were also used in the 
project, listed in Table 13.  
 
Table 13: Isolates generated by a previous master student Chon Kit Lam in the MicroPop research group. 
Strain MIC MEC (µg/ml) MIC CIP (µg/ml) 
K56-22 0,25 8-12 
K56-30 0,125 12-16  
 
As was seen with some mecillinam mutants, different phenotypes were observed in some of 
the ciprofloxacin mutants. These isolates were either successfully purified or excluded from 
the project. However, this issue was not seen as frequently as for the mecillinam mutants. In 
some cases the mutation frequencies could not be determined due to dense growth 
covering the selective plates. 
The highest ciprofloxacin MICs above the clinical breakpoint were observed for strains K56-
29 and K56-23 (32 µg/ml), and the lowest was for strain K56-38 (6 µg/ml). All of the isolates 







4.3 Isolation of clinically resistant ciprofloxacin and mecillinam isolates 
We wanted to investigate if the presence of two resistance determinants, as well as the 
order of which these mutants were generated, would have an impact on CS and CR profiles. 
A selection of isolates resistant to ciprofloxacin or mecillinam were used to generate these 
double mutants. The same methods as for selection of resistance in single mutants was used 
to select for the secondary resistance trait. The aim was to achieve clinical isolates resistant 
to both mecillinam and ciprofloxacin above their clinical breakpoints.  
 
4.3.1 Mecillinam resistant isolates selected for ciprofloxacin resistance 
Five MEC mutants were chosen and selected on ciprofloxacin to obtain resistant isolates. 
Between one to five resulting isolates were selected and purified for each strain (Table 14), 
and they were further tested using MIC gradient diffusion strips.  








Step 1 Step 2 Step 3 



























K56-26 II 6,67x10-10 ND  I ND 3 
K56-30 IV 1,62x10-10 3,7x10-10   ≥256 6 
ND: MIC not determined. 
 
Although the process of selecting mecillinam resistant isolates with ciprofloxacin didn’t 
require more selection steps than for the single ciprofloxacin resistant isolates, it was 





incubated for two days due to slow growth, and the colonies were often very small. Variable 
phenotypes were frequently observed, and purification and separation attempts were 
performed without success for some of the strains. Interestingly, one isolate, K56-29 MEC, 
lost its resistance to mecillinam after becoming resistant to ciprofloxacin. 
An interesting observation is the high MIC values for mecillinam, being ≥256 µg/ml for all the 
isolates. Such high MIC values has just been observed in two of the mecillinam mutants 
generated. The MICs for CIP are more variable, ranging from 3 up to 32. All the strains were 
identified as E. coli by MALDI-TOF. 
 
4.3.2 Ciprofloxacin resistant isolates selected for mecillinam resistance 
Five CIP mutants were selected on mecillinam to obtain them resistant isolates. The mutants 
were struck on plates with concentration of 8 µg/ml and 16 µg/ml of mecillinam. Three to 
five colonies with different phenotypes were isolated and purified for each strain, and they 
were further tested using MIC gradient diffusion strips. The isolates that were successfully 
purified and found to be resistant above the clinical breakpoints are listed in the Table 15 
below. 










K56-22 I ND I 3 ND 



































All the mutants had to be incubated for two days as the colonies appeared extremely small 
after only one day of incubation. At day two, the colonies were still rather small on both 
MEC8 and MEC16 plates. For two of the isolates, K56-22 CIP and K56-30 CIP, the plates were 
fully covered in colonies, thus mutation frequencies could not be determined.  
For these double mutants, a high MIC value above the limit of detection ≥256 µg/ml for 
mecillinam was observed for all the isolates except K56-22, which was difficult to interpret. 
The MI Cs for ciprofloxacin are above the clinical breakpoint and range between 3 to 12. 
 
4.4 IC90 determination and assembly of collateral susceptibility networks 
The generated mutants and their WT parental strains were further characterized by 
determining IC90 values to investigate how the selection for resistance may have affected 
their susceptibility to six other antimicrobials; AZT, CHL, CIP, GEN, MEC and TMP. These were 
chosen based on previous results to investigate if trends observed for other isolates could be 
confirmed. The drugs were chosen to test trends of increased sensitivity, increased 
resistance as well as no change in susceptibility following generation of mutants resistant to 
either CIP or MEC. 
An initial 2-fold dilution scheme was used to increase the range of concentrations tested and 
improve the probability of determining the IC90 This initial testing was followed by a final IC90 
determination using a 1,5-fold dilution to achieve more precise values. The OD600 was 
measured after 18 hours and after 42 hours for some slow-growing mutants. Results from 
the 1,5-fold experiment were used to calculate fold changes by comparing the resistant 
isolates to their WT parental strains. The resulting fold changes are presented in following 
heatmaps where they are illustrated by colors of varying intensities. Decreases in 
susceptibility indicating a fold change equal to or above 1,5 are highlighted in red (CR), and 
for simplicity described as positive fold-changes. An increase in susceptibility or a fold 
change equal to or less than -1,5 fold are highlighted in blue (CS) and is for simplicity 
described as negative fold-changes. Isolates that did not show a relevant change in 






4.4.1 Collateral sensitivity profiles of mecillinam resistant isolates 
The mecillinam resistant isolates all displayed reduced susceptibility above the clinical 
breakpoint for mecillinam and 64-341 fold increases in IC90 (Figure 9). Further analyses of 
the collateral networks revealed that CS or no change in susceptibility are the dominant 
trends among these mutants. More specifically, CS was observed in all of the mecilinam 
resistant isolates towards AZT and GEN; the largest increase in susceptibility was observed in 
K56-22 towards AZT with a fold range of -3,33. However, the exceptions are isolate K56-29, 
which shows CR to GEN and isolate K56-30 that has no change in its susceptibility to AZT. 
Towards CIP, most isolates showed no change in susceptibility. 
Figure 9: Collateral sensitivity network of mecillinam resistant mutants. Heatmap describing fold changes for 
collateral sensitivity (CS) and cross-resistance (CR) in nine mecillinam resistant isolates compared to their WT 
parental strains. 
Some of the generated mecillinam mutants are not shown in this heatmap, as they were 
excluded during the IC90 experiment. The K56-73 and K56-63 isolates were extremely slow 
growing, even after 42 hours, so accurate IC90 values based on OD measurements could not 





highest MIC-values of ≥256 in the gradient-strip diffusion test. Another strain, K56-22, was 
also slow growing, but was characterized by IC90 testing, as the OD600 of the positive control 
ended above 0,3. Finally, isolate K56-35 was excluded as it was found have an IC90 result for 
mecilinam that was below the clinical breakpoint. 
 
4.4.2 Collateral sensitivity profiles of ciprofloxacin resistant isolates  
As expected, all the ciprofloxacin resistant isolates showed reduced susceptibility above the 
clinical breakpoint for ciprofloxacin with 342-12,288 fold increases in the IC90. However, one 
of the isolates, K56-25, was included in this heatmap although it was slow growing. As the 
positive control did not increase that much after 42 hours, the 18-hour value has been used. 
 
Figure 10: Collateral sensitivity network of ciprofloxacin resistant mutants. Heatmap describing fold changes 
for collateral sensitivity (CS) and cross-resistance (CR) in eight ciprofloxacin resistant isolates compared to their 
WT parental strains. 
Analyses of the collateral networks show that a decrease in susceptibility is commonly 





AZT. For MEC only one isolate shows displayed CR, while the others has no change or an 
increase in sensitivity. However, GEN stands out from the other drugs, as CS is present in all 
the isolates with fold changes ranging between -1,5 to -4 and an average value of -2,44. 
 
4.4.3 Collateral sensitivity profiles of isolates resistant to both ciprofloxacin and mecillinam  
The ciprofloxacin and mecillinam resistant isolates all displayed reduced susceptibility above 
the clinical breakpoint (256-512 and 42,7-256 fold increases in IC90, respectively). However, 
two of the generated double mutants, K56-25 M/C and K56-26 C/M, were excluded in this 
heatmap as the IC90 testing revealed that they are not clinically resistant to mecillinam. In 
addition, the isolates that were observed as slow growing among the single mutants, K56-22 
and K56-25, were also slow growing as double mutants.  
 
 Analyses of the collateral networks show that the CR effects seen for the CIP mutants to a 
certain degree dominate the effects caused by MEC resistance. Another interesting 
observation is that CS to GEN was observed in all isolates with fold changes ranging from -
2,63 to -5,26, a trend that was also observed in the isolates resistant to CIP or MEC 
individually. 
Figure 11: Collateral sensitivity network of ciprofloxacin and mecillinam resistant mutants. Heatmap 
describing fold changes for collateral sensitivity (CS) and cross-resistance (CR) in ciprofloxacin and mecillinam 






4.5 Biofilm formation 
 
4.5.1 Optimization of biofilm essay on E. coli 
To decide the most suitable growth media to be used for further investigation of biofilm 
formation in clinical resistant E. coli isolates, five WT strains and RP62A were tested with six 
different growth media; LB, MH, TSB with 1% glucose (TSBglu), TSB, BHI and M9.  
The average biofilm formation, shown in the diagram below, indicates there was no major 
difference in the amount of biofilm being formed in the different E. coli strains. However, 
there were much greater biofilm formation observed in the control strain RP62A tested in 
TSBglu than the other growth media; this growth media was therefore selected for further 
use in the project. 
 
Figure 12: Biofilm formation in control strain RP62A and E. coli WT strains. Diagram displaying biofilm 
formation of E. coli WT strains and control strain in different growth medium. 
 
4.5.2 Determination of biofilm formation in clinical resistant isolates 
The isolates confirmed to be resistant to ciprofloxacin, mecillinam or ciprofloxacin and 
mecillinam (double mutants) were tested to investigate if the mutations that were selected 





to in fact only be resistant to one drug were also included in the analysis. The different 
isolates, their WT parental strains and a control strain were tested, and the OD570 was 
measured. Three replicates were performed and the average value of these replicates was 
calculated.  
 
The results show that biofilm formation is low for all the mutants (Figure 13). While the 
control strain usually has an OD570 value between 3,7-4, the highest observed value in the 
mutants is 0,56 in K-56 25 M/C double mutant which is only resistant to CIP, and the lowest 
measurement of 0,07 was from the K56-38 CIP isolate.   
Figure 13: Biofilm formation in clinically resistant isolates. Diagram displaying biofilm formation in the 
different mutants generated in TSB with 1% glucose. 
 
There is no clear trend in the biofilm formation of the antibiotic resistant mutants compared 
to their WT. Four of the twelve WTs produce more biofilm than all their mutants. Seven of 
the ten mecillinam mutants also produce more biofilm than their respective WTs. For the CIP 
mutants, only two out of the eight are forming more biofilm than their WTs.  However, the 
MEC mutants generally have a slightly higher value than the CIP mutants of the same strain, 
















The escalating emergence of AMR is a growing public health concern. The acceleration of 
bacterial evolution causing resistance to antibiotics is an inevitable outcome of the use and 
misuse of antibiotics since its introduction in the 1940s [51]. As the development of new 
drugs has stagnated, there is a need to investigate novel strategies that can contribute to 
extend the efficacy of antimicrobial agents. One approach may be to achieve a better 
understanding of the phenomena of CS, a side-effect in the evolution of AMR. As proposed 
by Imamovic and Sommer, reciprocal CS can be applicable in drug cycling, suppressing the 
emergence of resistant bacteria [1]. The main focus in this study is to further investigate 
these phenomena by evolving resistance in clinical strains of E. coli from UTIs, and to 
investigate the biofilm forming abilities of the isolates.   
 
5.1 CS and CR effects 
Our results show that the resistant isolates of CIP and MEC demonstrated different CS and 
CR effects in clinical isolates of E. coli. CS was frequently observed in the MEC resistant 
mutants in comparison to CR, which was only shown in one MEC resistant isolate for GEN 
and TMP. In contrast, CR more frequently appeared than CS in the CIP mutants. CR was seen 
in most isolates for TMP and CHL. Also for AZT this effect is dominating. These results are 
consistent with an ongoing study in the MicroPop research group based on single resistance 
determinants in clinical E. coli strains (Podnecky et al, unpublished results). 
The effect of more than one resistance determinant on collateral networks is currently 
unknown. To the best of my knowledge, we here present the first data on collateral 
networks of clinical E. coli strains resistant to both CIP and MEC. Interestingly, it looks like 
the isolates being resistant to both CIP and MEC tend to be largely dominated by the CR 
effects seen for the isolates resistant to CIP alone. In this study, we have not investigated the 
underlying mutations causing resistance in our isolates. In MEC resistant isolates, there are 
numerous genes that may confer resistance to the drug, making it difficult to predict what 
kind of mutations that have occurred in our mutants [37]. However, it is known that 





in the regulation of efflux pumps. This may be an explanation for the high CR interactions 
observed when CIP develops resistance [45]. The CR effects was especially clear in isolate 
K56-30 where it is seen to all drugs except from GEN. Moreover, these isolates were not 
affected by the order of which they were generated, as the network appear to be identical. 
However, the order of which the isolates were generated may have influenced the CS and CR 
profiles for the isolates derived from strain K56-22. In the MEC resistant isolate selected for 
CIP resistance, CS are the dominating effect observed. For the other isolate, a combination 
of CR and CS was seen. In two of the isolates, K56-25 and -26, we were not able to generate 
clinically resistant isolates to CIP and MEC in both orders for comparison. However, for these 
isolates a combination of CS and CR effects was seen. Taken together, these results strongly 
suggest that collateral networks identified in strains resistant to single antimicrobials needs 
to be interpreted with caution. It is clear that certain combinations of resistance 
determinants may affect these networks. It is therefore necessary to further explore CS and 
CR effects beyond single resistance determinants.  
An important overall observation in our results is the CS effects observed to the 
aminoglycoside GEN. Except for one MEC resistant isolate, all the other clinically resistant 
isolates displayed CS effects to this drug. The MicroPop research group did a similar study 
where they investigated and displayed CS and CR effects in a heatmap by using IC90 assays. 
When comparing our results to their findings, we can see similar pattern of CS and CR 
profiles in CIP and MEC resistant isolates (see Section 1.9.1). The observation that CR effects 
more frequently occur in CIP mutants, as well as a strong tendency of CS to GEN, are 
consistent with our results. For the MEC resistant isolates, the MicroPop group observed 
that an increase or no change in susceptibility to different drugs are dominating the 
network, as well as that CS appear more frequent than the CR effects seen for the CIP 
mutants. Their results also show that CS frequently occur to AZT in MEC resistant isolates, 
like our results. Half of their MEC resistant isolates displayed CS to gentamicin. 
 
5.1.1 Comparison to previous studies 
In Imamovic and Sommers study from 2013, they evolved resistance to single drugs from 





of antibiotics. CS and CR were determined by IC90 assays and they displayed their results in a 
heatmap [1]. Like our findings, they observed CR patterns to AZT, CHL and TMP in their CIP 
resistant isolates. However, CS in GEN is not described in their results. As Imamovic and 
Sommer did not evolve isolates resistant to MEC, we are comparing our results for the MEC 
resistant isolates to β-lactams in their study. They included five drugs from this class of 
antibiotics. Unlike our results, Imamovic and Sommer frequently observed CR patterns in β-
lactam resistant isolates. CR was seen to CIP, CHL, AZT and TMP in all the five drugs included, 
which is distinctly different from our results. In addition, CS to GEN was seen in cefuroxime 
only.  
Lazar published a similar study in 2013, short time after Imamovic and Sommer. They 
evolved resistance to single drugs, using 12 antimicrobials, in a single ancestral clone of E. 
coli and mapped networks of CS interactions to a number of agents. Additionally, they tried 
to explain the underlying mechanisms of the CS they observed [52]. They did not include 
MEC in the study, thus we compare our results for the MEC resistant isolates to the drugs 
having the equivalent mechanism of action as MEC, the cell-wall inhibitors. Like for our 
results, they observed CS effects to GEN in resistant isolates of both CIP and the cell-wall 
inhibitors from the adaption to low antibiotic concentrations [52]. In a similar study 
published by Lazar a in 2014, they focused on networks of CR interactions by generating E. 
coli populations from one single ancestral clone resistant to 1 of 12 antibiotics in total [53]. 
Here they observed CR in the CIP resistant isolates to TMP. For the cell-wall inhibitors, CR 
interactions were observed to TMP, CIP and CHL [53]. 
In conclusion, this report and ongoing activitiy in MicroPop research group highlight the 
need for addressing collateral networks in large collections of clinical strains to identify 
conserved patterns that may inform future treatment protocols. Previous published studies 
investigating CS and CR are focusing on single laboratory strains. Investigating clinical 
isolates of diverse genetic background is a strength in our study. These strains exhibit 
variations of susceptibility and give us a broader insight in CS and CR profiles on a population 
level. However, our findings are based on in vitro results, and a subject that remains to be 
explored is if CS can be used in clinical setting. Further in vivo studies have to be performed 






5.1.2 Clinical relevance of our findings 
Our findings may be helpful in future treatment strategies to select against AMR in clinical 
isolates being resistant to CIP and/or MEC, two important drugs in the treatment of UTIs. 
Our results suggest that MEC is a suitable drug of choice in the treatment of UTIs, consistent 
with current guidelines in Norway. CR towards the other drugs tested were not frequently 
observed, and CS effects of this drug may be taken advantage of in collateral drug cycling. 
Additionally, long term use of this antibiotic has shown that resistance to MEC is rare in vivo, 
despite that resistance is easily obtained in the laboratory [37]. Thulin and co-workers 
recently suggest that this probably is an effect of the physiology and mechanistic host 
defences such as bladder emptying and urine flow, making it difficult for the bacteria to 
maintain and develop resistance in the bladder [37]. The ECO∙SENS studies also show that 
the level of resistance to MEC is low, as the prevalence in Europe was 1,6% in 2008-2009 
[32]. 
Our results also show that treatment with CIP may lead to CR to several other drugs, making 
it a less suitable choice in the treatment of UTIs. In contrast to MEC, this antibiotic is 
extensively used worldwide in the treatment of  several Gram-positive and Gram-negative 
infections, and resistance to CIP and other fluoroquinolones occur at an increasing rate in 
several bacterial species [46]. This is confirmed by the ECO∙SENS studies, as the prevalence 
of ciprofloxacin resistance increased from 1,1% (1999-2000) to 3,9% (2008-2009) [32].  
An important finding in our study is the CS effects observed in all the resistant isolates 
towards the aminoglycoside GEN, an important broad spectrum antibiotic used in the 
treatment of a wide range of infections worldwide [54]. This drug is frequently used in 
hospital acquired infections of multidrug-resistant Gram-negatives [55]. Aminoglycosides are 
also an interesting class of antibiotics as previous studies show a wide range of CS effects to 
other antibiotics when resistance develops in these drugs [1, 52]. The theory behind 
Imamovi and Sommer’s drug cycling is based on reciprocal CS. In order to test if their cycling 






5.2 Biofilm formation in clinical resistant E. coli isolates 
One goal in this study was to investigate whether the mutations occurring in the clinically 
resistant E. coli isolates affect their ability to produce biofilms. Before determining biofilm 
formation in the resistant isolates, an optimization experiment was performed to decide the 
most suitable growth media to be used further in the experiment, as the biofilm formation 
can be variable in different growth media/culture conditions [56]. There was no significant 
difference between the different media tested, but TSBglu were chosen due to a greater 
biofilm formation observed in the control strain RP62A. 
Our results show that the selected mutants and their WT parental strains are generally 
producing little biofilm compared to the positive control, Staphylococcus epidermidis RP62A, 
a well-known strong biofilm producer. Four of the twelve WTs produce more biofilm than all 
of their respective mutants. For the CIP mutants, only two out of the eight are forming more 
biofilm than their WTs. However, seven of the ten MEC mutants were shown to produce 
slightly more biofilm than their WT parental strains. 
 
However, different methods could also have been tried in this experiment, as this may 
influence the production of biofilm. Methods such as flow cell, tube test, Calgary biofilm 
device, congo red agar and biofilm reactor are examples  
 
5.3 Challenges and limitations in our study 
 
5.3.1 Limitations in the IC90 assay 
By comparing the results from the 2-fold dilution and the 1,5-fold dilution, the results usually 
matched each other well. However, the results were not always consistent, as different data 
were observed between the two experiments (see Appendix F). Using CIP resistant isolates 
as an example, the IC90 in the 2-fold dilutions sometimes appeared to be higher (>16) than 
determined in the experiment using the 1.5-fold dilution. This is likely a result of human 
error during the experiment. The 2-fold and 1,5-fold dilution experiments were only 
performed once. The exception was for some of the 1,5-fold dilutions that had to be 





predicted range. In order to ensure correct IC90 values and achieve more precise results, the 
experiments should be performed more than once.  
One observation in the IC90 assay was the appearance of slow growing strains. For the MEC 
mutants, the highest MICs above the clinical breakpoint were for strains K56-63 and K56-76 
(≥256 µg/ml). In liquid MH medium, MEC mutant K56-73 did not grow at all, whereas clear 
growth was observed in LB after overnight incubation. This indicates that MH II broth lack 
some kind of nutrient essential for this isolate. MEC mutant K56-63 was extremely slow 
growing, having an OD600 of 0,27 in the positive control after 42 hours of incubation. These 
MEC resistant isolates were excluded from analysis. Thulin had similar observations when 
measuring growth rate of MEC mutants in MH medium, where the relative growth rates 
ranged from 0,25-0,7 [37]. They suggest that this may be due to reduced growth rate 
associated with severe fitness costs, which is frequently observed when MEC resistance is 
acquired in the laboratory [37].  
Reduced growth rates were also seen in MEC mutant K56-22 and CIP mutant K56-25, as well 
as their generated double mutants. These resistant isolates were characterized by IC90 
testing, as the OD600 of the positive control ended above 0,3. However, including these 
mutants may have influenced the result as its not completely precise, and has probably 
underestimated the IC90 value. 
 
 
5.3.2 Challenges and limitations in generating and confirming clinical resistance 
A challenge in the confirmation of clinically MEC mutants, are spontaneous mutations 
frequently being observed in the zone of inhibition when interpreting MIC values by gradient 
diffusion strips. Many mutations can lead to MEC resistance [37]. This is the likely cause of 
the problem of purifying MEC mutants, as and also the reason for the observed spontaneous 
mutants observed when using E-test. 
However, another interesting observation for the clinical isolates being resistant to both CIP 
and MEC, is the high MIC-values observed in all the isolates towards MEC by performing E-
test, which were over the detection limit of the gradient diffusion strip (≥256 µg/ml) for all 
isolates except one. As described above, a possible explanation for these high values may be 
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6 CONCLUSION AND FUTURE ASPECTS 
 
We conclude that the favourable CS and CR profile in MEC resistant isolates possibly makes 
it an applicable drug to use in the first-line treatment of UTIs. Our results also confirm that 
CR is frequently observed in CIP resistant isolates, indicating that this drug should be used 
prudently due to the risk of resistance development to several other drugs. These 
suggestions are supported by the results from the MicroPop research group, showing similar 
patterns of CS and CR as in this study. Furthermore, our findings in the isolates resistant to 
both CIP and MEC show that the CR profile in CIP resistant mutants are able to dominate 
over the CS effects in MEC resistant mutants. This is an unnerving observation, considering 
the fact that most clinical E. coli isolates are resistant to several drugs. This might indicate 
that collateral sensitivity based drug cycling will not have the desired effects of steering 
bacteria on an evolutionary trajectory towards increased antimicrobial sensitivity in real life 
settings in vivo. Also, the gap in knowledge on how transferrable resistance determinants 
might affect collateral sensitivity networks, leaves a considerable amount of research still 
left to determine if collateral sensitivity cycling can work. However, the CS effects to GEN, 
seen in all the resistant isolates generated in this study, except for one MEC mutant, 
suggests that GEN may have some promise to be used as a part of collateral drug cycling to 
other drugs showing reciprocal CS. 
There are several unanswered questions regarding collateral susceptibility changes that 
should be further investigated. First of all, there is a need to perform future studies on 
various bacterial species of diverse genetic backgrounds to achieve a broader insight in these 
effects on a population level. There is also a need to achieve more knowledge of the 
underlying mechanism(s) of CS in order to get a better understanding of this phenomenon. 
There should also be performed studies in order to achieve a better understanding of how 
single-determinant data will be affected in strains being resistant to more than one drug. 
There is also a need to investigate whether CS can be used in clinical setting. Further in vitro 
and vivo studies have to be performed to answer this knowledge gap. 
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When determining biofilm formation, we can observe that our resistant isolates generally 
are not producing much biofilms, which is a positive observation due to their ability to 
complicate the treatment of infections. However, considerable more in vitro studies, testing 
the isolates with different methods is needed to determine this. We did not observe any 
highly significant trends towards collateral changes in biofilm forming ability following the 
resistance mutations. However, the observation of a trend towards more biofilm-
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MIC MEC (µg/ml) 






K56-30 7,1x108 23 3,24x10-8 IV 0,016 32 
K56-35 2,49x109 51 2,05x10-8 V 0,032 8-12 










K56-76 4,63x109 997 2,15x10-7 I 0,016 8 
K56-77 1,46x109 139 9,5x10-8 I 0,023 24 
K56-80 3,75x109 396 1,06x10-7 III 0,012 24-32 
 
 
Appendix B: Results from static selection of ciprofloxacin resistant mutants. 
 






























































































ND: Mutation frequency not determined due to dense growth on selection plate. 
 
 











Step 1 Step 2 Step 3 



























K56-26 II 6,67x10-10 ND  I ND 3 
K56-30 IV 1,62x10-10 3,7x10-10   ≥256 6 















Isolated mutants MIC CIP (µg/ml) MIC MEC (µg/ml) 
K56-22 I ND I 3 ND 
 







































Organism (best match) Score 
value 




A1 1 Escherichia coli 2,364 Escherichia coli 2,322 
D1 1 Escherichia coli 2,408 Escherichia coli 2,314 














Appendix F: IC90 determination. Tested against six different antimicrobials on parental 










IC90 2-fold IC90 1,5-fold 
Fold change 

























































































































































































































































































































































IC90 2-fold IC90 1,5-fold 
Fold change 































































































































































































































































































































































IC90 2-fold IC90 1,5-fold 
Fold change 































































































































































































































































































































































IC90 2-fold IC90 1,5-fold 
Fold change 

























































































































































































































































































































































IC90 2-fold IC90 1,5-fold 
Fold change 




































































































































































































































































































































































IC90 2-fold IC90 1,5-fold 
Fold change 
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Average value  


























































































































































































































































 K56-80 WT 
K56-80 MEC 
0,1344 
0,2905 
 
0,2781 
0,2433 
 
0,1535 
0,1960 
 
0,1887 
0,2433 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
80 
 
 
